* The newly launched dedicated centre for HIPEC and Cytoreductive Surgery is expected to build on the hospital’s experience by bringing together the infrastructure, specialist expertise and coordinated clinical support required for this demanding treatment.

R ARIVANANTHAM
CHENNAI, NOV 18
When cancer spreads to the delicate lining of the abdomen, treatment can become especially challenging. What if surgery could remove visible tumour deposits and heated chemotherapy could then be delivered directly into the abdominal cavity to target cancer cells too small to be seen? Kauvery Hospital, Chennai, has crossed a significant institutional milestone in this specialised approach, completing more than 200 procedures involving Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and launching a dedicated centre for HIPEC and Cytoreductive Surgery.
- Specialised surgery-plus-heated-
chemotherapy approach targets cancers spreading to the abdominal lining - Milestone positions hospital among a select group of centres in Tamil Nadu with such experience
- HIPEC seeks to destroy microscopic cancer cells left after surgical removal of visible tumours
- Ovarian, colorectal and other peritoneal cancers among conditions treated in carefully selected patients
- New dedicated centre to bring surgical, medical oncology and critical-care expertise under one roof
- Multidisciplinary team, specialised equipment and precise patient selection are central to the complex procedure
The achievement highlights the growing role of specialised, multidisciplinary cancer care in addressing malignancies that have spread to the peritoneum—the membrane lining the abdominal cavity. The hospital said the milestone places it among the few centres in Tamil Nadu with this level of experience in treating such cancers.
Surgery and heated chemotherapy: A combined approach
HIPEC is not a stand-alone chemotherapy procedure. It is performed in conjunction with cytoreductive surgery, in which surgeons aim to remove all visible tumour deposits from the abdominal cavity.
After the surgical removal of visible disease, heated chemotherapy is circulated directly within the abdomen, generally at approximately 41–43°C. The objective is to target microscopic cancer cells that may remain after surgery.
Delivering chemotherapy directly at the disease site allows concentrated treatment within the abdominal cavity, while limiting the amount of the drug reaching the rest of the body. The approach is intended to address a key challenge in treating peritoneal disease, where conventional intravenous chemotherapy may not adequately reach all cancer deposits.
A treatment option for carefully selected patients
HIPEC is considered for selected patients whose cancers have spread within the abdominal cavity. These include ovarian and colorectal cancers, along with other malignancies involving the peritoneal lining.
However, it is not suitable for every patient with advanced cancer. The extent of disease, the possibility of removing visible tumour deposits and the patient’s overall medical condition are important considerations in deciding whether the procedure is appropriate.
Advanced imaging and, where required, laparoscopic staging help assess the spread of disease and identify patients most likely to benefit.
Why the procedure demands a specialised team
The success of the treatment depends substantially on the expertise involved in cytoreductive surgery, particularly the extent to which visible cancer deposits can be removed.
The procedure requires a coordinated team of surgical oncologists, medical oncologists, anaesthetists, intensivists, pathologists, radiologists and nutritionists, supported by nurses experienced in managing complex cancer cases.
Specialised perfusion equipment is used to heat the chemotherapy solution, circulate it within the abdominal cavity and continuously monitor its temperature. As the operation can be prolonged and may involve significant blood loss and heat stress, experienced anaesthesia and critical-care teams are essential throughout the procedure and recovery.
200 procedures: Experience built on teamwork
Commenting on the milestone, Dr Sujay Susikar, Senior Consultant – Surgical Oncology, Kauvery Hospital, said:
“We are happy to have crossed the milestone of 200 HIPEC procedures, which reflects our team’s experience and commitment to delivering advanced cancer care. HIPEC offers an important treatment option for patients with advanced cancers that have spread to the peritoneum, a condition that was once considered extremely difficult to treat. Conventional intravenous chemotherapy may not adequately reach cancer deposits in this region. HIPEC addresses this limitation by circulating heated chemotherapy directly within the abdominal cavity following surgery to remove visible tumours. This helps target microscopic cancer cells that may remain after surgery, improving treatment possibilities for carefully selected patients who previously had very limited options.”
Expanding access to complex cancer care
Underlining the hospital’s broader vision, Dr Aravindan Selvaraj, Co-Founder and Executive Director, Kauvery Group of Hospitals, said:
“Advanced abdominal cancers have always been among the most challenging to treat. With HIPEC, we are able to extend meaningful treatment options for patients who earlier had very limited choices. At Kauvery Hospital, our focus has been on combining the right infrastructure, clinical expertise, and a multidisciplinary approach to deliver outcomes that truly make a difference in patients’ lives. This integrated approach has also enabled us to care for patients from across geographies, who place their trust in our team for complex cancer treatment.”
The milestone is a reminder that advances in cancer care are not defined by technology alone. In complex abdominal malignancies, the ability to select the right patient, remove visible disease as completely as possible and deliver carefully coordinated treatment can be central to expanding therapeutic possibilities.
